Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-sirolimus + adagrasib
- Development stage
- Discontinued
- Lead developer
- Aadi Bioscience
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
nab-sirolimus + adagrasib is an investigational combination therapy consisting of nab-sirolimus (Fyarro), an intravenous nanoparticle albumin-bound formulation of the mTOR inhibitor sirolimus, and adagrasib (Krazati), an oral small-molecule inhibitor of mutant KRAS G12C. Developed through a clinical collaboration between Aadi Bioscience and Mirati Therapeutics (now a subsidiary of Bristol Myers Squibb), this combination is designed to simultaneously inhibit the mTOR and KRAS G12C signaling pathways. Preclinical studies demonstrated that dual inhibition of these pathways addresses key bypass and feedback resistance mechanisms, leading to enhanced anti-tumor activity compared to either agent alone. The combination was evaluated in the Phase 1/2 KRYSTAL-19 trial (NCT05840510) for patients with advanced solid tumors and non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation; however, the trial was terminated in 2024 due to changes in business objectives.
- Other names
- Fyarro + KrazatiKrazati + Fyarroadagrasib + nab-sirolimusadagrasib plus nab-sirolimusnab-sirolimus plus adagrasib
02
Targets
CDK7FKBP1AKRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on nab-sirolimus + adagrasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-sirolimus + adagrasib.